Recent developments raise the bar for cost-effectiveness of the combination of Yervoy/Opdivo

Opdivo is a PD-1–blocking antibody that so far has gained a label in 11 broad oncology indications in the US. Credit: Evgeniy Kalinovskiy/Shutterstock.